Apollo Hospitals Q4 FY25: Profit up 53.5%, dividend Rs 10

Key takeaways for investors

Apollo Hospitals Enterprise posted a sharp year-on-year rise in profitability in Q4 FY25, alongside steady revenue growth. The board also recommended a final dividend of Rs 10 per share for FY25, fixing August 19, 2025 as the record date. Separately, the company later declared an interim dividend of Rs 10 per share for FY2025-26, with a February 16, 2026 record date and payment due on or before February 27, 2026.

Q4 FY25 results: profit beats Street estimates

For Q4 FY25, Apollo Hospitals reported net profit of Rs 390 crore, up 53.5% year-on-year from Rs 254 crore in the same quarter last year. The performance exceeded Street estimates, as cited in the provided data.

Revenue from operations in Q4 FY25 rose 13% year-on-year to Rs 5,592 crore, compared with Rs 4,944 crore in Q4 FY24. Sequentially, the article notes Profit After Tax (PAT) increased 5% versus Rs 372 crore reported in Q3 FY25, while revenue was marginally up 1.2% from Rs 5,527 crore in the October-December quarter of FY25.

Expenses in Q4 FY25 were Rs 5,148 crore, compared with Rs 5,060 crore in Q3 FY25 and Rs 4,612 crore in Q4 FY24.

Operating performance: EBITDA and margin trend

Apollo Hospitals reported EBITDA of Rs 769.9 crore in Q4 FY25, up 20% from Rs 640.5 crore in Q4 FY24. EBITDA margin improved to 13.8% in Q4 FY25 from 13% in Q4 FY24.

These operating metrics complement the headline profit growth and indicate that the quarter’s earnings expansion was supported by improved operating profitability, not just revenue growth.

Segment snapshot in Q4 FY25

The article provides a segmental view for Q4 FY25:

• Revenue from healthcare services increased 10% year-on-year to Rs 2,822 crore.
• Apollo Health and Lifestyle (AHLL) revenue stood at Rs 394 crore, up 11% year-on-year.
• Apollo HealthCo revenue was Rs 2,376.3 crore, up 17% year-on-year.

This split highlights growth across the core hospital services business as well as the company’s consumer-facing health and pharmacy-related operations.

FY25 full-year numbers

On a full-year basis, Apollo Hospitals reported consolidated net profit of Rs 1,445.90 crore in FY25, up 60.9% year-on-year. Consolidated revenue from operations for FY25 rose 14.3% to Rs 21,794 crore.

The FY25 numbers provide context to the Q4 print, showing that the company’s growth in profits was not limited to a single quarter.

Dividend: final dividend for FY25 and record date

The board recommended a final dividend of Rs 10 per equity share (face value Rs 5) for FY25. The record date for determining eligible shareholders was fixed as Tuesday, August 19, 2025.

The final dividend was stated as subject to shareholder approval at the company’s Annual General Meeting (AGM) scheduled for August 29, 2025. If approved, the dividend is expected to be paid on or before September 10, 2025.

Eligibility detail under T+1 settlement

The article also notes the practical implication of the record date under India’s T+1 settlement cycle. To qualify for the FY25 final dividend, investors needed to purchase Apollo Hospitals shares on or before August 18, 2025, so that ownership would reflect in the demat account by the record date of August 19, 2025.

Interim dividend for FY2025-26: dates and schedule

For FY2025-26, the board declared an interim dividend of Rs 10 per share (described as 200% of the face value of Rs 5 per share). The record date was fixed as February 16, 2026, and payment was scheduled on or before February 27, 2026.

These dates are distinct from the FY25 final dividend timeline and relate to the financial year ending March 31, 2026.

Q3 FY26 update: profit, revenue, PBT, EBITDA and segment mix

In the quarter ended December 31, 2025 (Q3 FY26), Apollo Hospitals reported a 34.91% surge in consolidated net profit to Rs 502.29 crore on a 17.19% increase in revenue from operations to Rs 6,477.40 crore versus Q3 FY25.

Profit before tax (PBT) rose 27.19% year-on-year to Rs 682 crore. EBITDA increased 26.64% to Rs 965 crore in Q3 FY26 from Rs 762 crore in Q3 FY25.

Segmental revenues in Q3 FY26, as stated:

• Healthcare Services: Rs 3,183 crore, up 14% year-on-year.
• Apollo Health and Lifestyle (AHLL): Rs 467 crore, up 20% year-on-year.
• Apollo HealthCo: Rs 2,827 crore, up 20% year-on-year.

Stock move cited after Q3 FY26 results

The provided text notes that Apollo Hospitals Enterprise jumped 5.09% to Rs 7,587.25 after the company reported its Q3 FY26 results.

Standalone snapshot disclosed for December 2025 quarter

The company also disclosed unaudited standalone results for the quarter ended December 31, 2025:

• Total Income (Standalone) reached Rs 2,471.7 crore (Rs 24,717 million), up from Rs 2,162.7 crore (Rs 21,627 million) in the corresponding quarter last year.
• Standalone PAT stood at Rs 381.1 crore (Rs 3,811 million), compared with Rs 339.1 crore (Rs 3,391 million) in the previous year’s quarter.

Summary table of key facts

Why the developments matter

The combination of strong Q4 FY25 earnings and a clear dividend timeline gives shareholders visibility on cash returns, subject to the required approvals. The later interim dividend declaration for FY2025-26 further signals continuing distributions alongside growth in quarterly financials reported for the December 2025 quarter.

The provided results also show how Apollo Hospitals’ segment mix is contributing to revenue growth, with healthcare services remaining the largest contributor and Apollo HealthCo and AHLL posting faster year-on-year growth rates in the cited periods.

Conclusion

Apollo Hospitals closed FY25 with higher profitability, reporting Q4 net profit of Rs 390 crore on revenue of Rs 5,592 crore and recommending a Rs 10 final dividend with an August 19, 2025 record date. For FY2025-26, it also declared a Rs 10 interim dividend with a February 16, 2026 record date, with payment scheduled on or before February 27, 2026.